Key result
The loss-of-function CYP2C19*2 allele had an allelic frequency of 40% in cardiovascular patients taking clopidogrel in North-East India, whereas CYP2C19*3 and *17 alleles were not found.
Cross-Sectional (n=60)
No
The CYP2C19*2 loss-of-function allele has a high carriage frequency (~40%) in cardiovascular patients from North-East India, highlighting the potential need for personalized antiplatelet therapy in this population.
High CYP2C19*2 prevalence may inform clopidogrel use in North-East India; extends allele-frequency data but leaves open clinical impact.
typically <1%, with the exception of CYP2C19*3 (c.636G>A; rs4986893) in Asians (2-9%) Based on identified CYP2C19 genotypes, individuals can be categorized as extensive metabolizers (e.g., *1/*1), intermediate metabolizers (e.g., *1/*2), or poor metabolizers (e.g., *2/*2) (Table The frequencies of CYP2C19 poor metabolizers are ~2-5% among Caucasians and Africans and ~15% in Asians. In contrast, the CYP2C19*17 allele (c.-806C>T; rs12248560) results in increased activity, with normal multi-ethnic allele frequencies of ~3-21% Individuals who possess this allele may be categorized as ultra-rapid metabolizers (e.g., *17/*17). Some studies reveals that this allele results in enhanced platelet inhibition and clopidogrel response However, other studies have not documented an effect of CYP2C19*17, and satisfactory evidence for an independent effect of this allele on clinical outcomes is missing In this study,
No takes yet. Share an insight, caveat, or question.
Vinayak S Jamd (2013) conducted a cross-sectional in Cardiovascular disease (n=60). CYP2C19 genetic variants vs. Wild-type alleles was evaluated on Allelic frequency of CYP2C19*2. The loss-of-function CYP2C19*2 allele had an allelic frequency of 40% in cardiovascular patients taking clopidogrel in North-East India, whereas CYP2C19*3 and *17 alleles were not found.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: